Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma
- PMID: 17507627
- DOI: 10.1158/1055-9965.EPI-06-1038
Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma
Abstract
Malignant melanomas often contain BRAF or NRAS mutations, but the relationship of these mutations to ambient UV exposure in combination with phenotypic characteristics is unknown. In a population-based case series from North Carolina, 214 first primary invasive melanoma patients in the year 2000 were interviewed regarding their risk factors. Ambient solar UV exposures were estimated using residential histories and a satellite-based model. Cases were grouped on the basis of BRAF and NRAS somatic mutations, determined using single-strand conformation polymorphism analysis and radiolabeled DNA sequencing, and the risk profiles of these groups were compared. Mutually exclusive BRAF-mutant and NRAS-mutant cases occurred at frequencies of 43.0% and 13.6% with mean ages at diagnosis of 47.3 and 62.1 years, respectively. Tumors from patients with >14 back nevi were more likely to harbor either a BRAF mutation [age-adjusted odds ratio (OR), 3.2; 95% confidence interval (95% CI), 1.4-7.0] or an NRAS mutation (age-adjusted OR, 1.7; 95% CI, 0.6-4.8) compared with patients with 0 to 4 back nevi. However, BRAF-mutant and NRAS-mutant tumors were distinctive in that BRAF-mutant tumors were characteristic of patients with high early-life ambient UV exposure (adjusted OR, 2.6; 95% CI, 1.2-5.3). When ambient UV irradiance was analyzed by decadal age, high exposure at ages 0 to 20 years was associated with BRAF-mutant cases, whereas high exposure at ages 50 and 60 years was characteristic of NRAS-mutant cases. Our results suggest that although nevus propensity is important for the occurrence of both BRAF and NRAS-mutant melanomas, ambient UV irradiance influences risk differently based on the age of exposure. The association of BRAF mutations with early-life UV exposure provides evidence in support of childhood sun protection for melanoma prevention.
Similar articles
-
BRAF and NRAS mutations in melanoma and melanocytic nevi.Melanoma Res. 2006 Aug;16(4):267-73. doi: 10.1097/01.cmr.0000222600.73179.f3. Melanoma Res. 2006. PMID: 16845322
-
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.Melanoma Res. 2006 Dec;16(6):471-8. doi: 10.1097/01.cmr.0000232300.22032.86. Melanoma Res. 2006. PMID: 17119447
-
Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas.J Invest Dermatol. 2016 Apr;136(4):829-837. doi: 10.1016/j.jid.2015.12.035. Epub 2016 Jan 22. J Invest Dermatol. 2016. PMID: 26807515
-
BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.J Clin Pathol. 2005 Jun;58(6):640-4. doi: 10.1136/jcp.2004.022509. J Clin Pathol. 2005. PMID: 15917418 Free PMC article. Review.
-
Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?J Invest Dermatol. 2006 Aug;126(8):1693-6. doi: 10.1038/sj.jid.5700458. J Invest Dermatol. 2006. PMID: 16845408 Review.
Cited by
-
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.JAMA Oncol. 2015 Jun;1(3):359-68. doi: 10.1001/jamaoncol.2015.0493. JAMA Oncol. 2015. PMID: 26146664 Free PMC article.
-
Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.J Invest Dermatol. 2018 Nov;138(11):2398-2404. doi: 10.1016/j.jid.2018.04.025. Epub 2018 May 9. J Invest Dermatol. 2018. PMID: 29753029 Free PMC article.
-
Emerging targeted therapies for melanoma treatment (review).Int J Oncol. 2014 Aug;45(2):516-24. doi: 10.3892/ijo.2014.2481. Epub 2014 Jun 3. Int J Oncol. 2014. PMID: 24899250 Free PMC article. Review.
-
Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.J Invest Dermatol. 2017 Dec;137(12):2588-2598. doi: 10.1016/j.jid.2017.07.832. Epub 2017 Aug 24. J Invest Dermatol. 2017. PMID: 28842324 Free PMC article.
-
Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis.Int J Cancer. 2009 Feb 15;124(4):937-44. doi: 10.1002/ijc.24011. Int J Cancer. 2009. PMID: 19035450 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous